AstraZeneca PLC Peer Comparison

Metric Value Ranking
Market Cap $226.5 Billion 4/12 LLY
$808.0B		 JNJ
$388.0B		 ABBV
$355.4B		 AZN
$226.5B		 MRK
$222.0B		 NVS
$218.0B		 AMGN
$164.8B		 PFE
$144.9B		 SNY
$140.5B		 GILD
$134.4B		 BMY
$120.1B		 GSK
$78.6B
Gross Margin 82% 1/12 AZN
82%		 LLY
82%		 MRK
81%		 NVS
75%		 ABBV
71%		 SNY
70%		 JNJ
68%		 GSK
68%		 PFE
67%		 AMGN
66%		 BMY
61%		 GILD
1%
Profit Margin 10% 6/12 LLY
33%		 MRK
27%		 GILD
24%		 NVS
21%		 JNJ
15%		 AZN
10%		 AMGN
7%		 SNY
7%		 GSK
5%		 PFE
2%		 BMY
1%		 ABBV
0%
EBITDA margin 30% 5/12 LLY
45%		 MRK
44%		 NVS
38%		 GILD
32%		 AZN
30%		 JNJ
26%		 AMGN
25%		 BMY
21%		 GSK
14%		 SNY
7%		 PFE
4%		 ABBV
4%
Quarterly Revenue $14.9 Billion 5/12 JNJ
$22.5B		 PFE
$17.8B		 MRK
$15.6B		 ABBV
$15.1B		 AZN
$14.9B		 NVS
$13.6B		 LLY
$13.5B		 BMY
$12.3B		 GSK
$10.4B		 AMGN
$9.1B		 SNY
$8.4B		 GILD
$7.6B
Quarterly Earnings $1.5 Billion 6/12 LLY
$4.4B 		MRK
$3.7B 		JNJ
$3.4B 		NVS
$2.8B 		GILD
$1.8B 		AZN
$1.5B 		AMGN
$627.0M 		SNY
$548.4M 		GSK
$530.8M 		PFE
$410.0M 		BMY
$72.0M 		ABBV
-$22.0M
Quarterly Free Cash Flow $2.0 Billion 7/12 ABBV
$6.8B 		JNJ
$4.8B 		AMGN
$4.4B 		BMY
$4.1B 		NVS
$3.1B 		GILD
$3.0B 		AZN
$2.0B 		GSK
$1.5B 		PFE
-$0 		MRK
-$0 		LLY
-$0 		SNY
-$0
Trailing 4 Quarters Revenue $54.1 Billion 6/12 JNJ
$88.8B		 MRK
$64.2B		 PFE
$63.6B		 SNY
$59.5B		 ABBV
$56.3B		 AZN
$54.1B		 NVS
$50.7B		 BMY
$48.3B		 LLY
$45.0B		 GSK
$40.2B		 AMGN
$33.4B		 GILD
$28.8B
Trailing 4 Quarters Earnings $7.0 Billion 7/12 JNJ
$22.5B 		PFE
$17.8B 		MRK
$15.6B 		ABBV
$15.1B 		AZN
$14.9B 		NVS
$13.6B 		LLY
$13.5B 		BMY
$12.3B 		GSK
$10.4B 		AMGN
$9.1B 		SNY
$8.4B 		GILD
$7.6B
Quarterly Earnings Growth 56% 4/12 MRK
405% 		PFE
112% 		LLY
101% 		AZN
56% 		GILD
25% 		GSK
18% 		JNJ
-15% 		AMGN
-18% 		NVS
-67% 		SNY
-75% 		BMY
-96% 		ABBV
-103%
Annual Earnings Growth 38% 3/12 LLY
425% 		PFE
176% 		AZN
38% 		MRK
32% 		NVS
-13% 		ABBV
-30% 		SNY
-30% 		AMGN
-31% 		GSK
-46% 		JNJ
-83% 		GILD
-94% 		BMY
-219%
Quarterly Revenue Growth 24% 3/12 LLY
45% 		PFE
25% 		AZN
24% 		NVS
15% 		AMGN
11% 		BMY
8% 		MRK
7% 		GILD
6% 		ABBV
6% 		JNJ
5% 		GSK
1% 		SNY
-67%
Annual Revenue Growth 16% 3/12 LLY
19% 		PFE
18% 		AZN
16% 		AMGN
15% 		BMY
9% 		NVS
6% 		JNJ
4% 		MRK
3% 		GILD
2% 		ABBV
0% 		GSK
-3% 		SNY
-11%
Cash On Hand $5.5 Billion 7/12 JNJ
$24.1B 		AMGN
$12.0B 		NVS
$11.5B 		BMY
$10.3B 		SNY
$8.2B 		ABBV
$5.5B 		AZN
$5.5B 		GSK
$4.7B 		PFE
-$0 		GILD
-$0 		MRK
-$0 		LLY
-$0
Short Term Debt $2.5 Billion 7/12 NVS
$8.3B 		ABBV
$6.8B 		JNJ
$6.0B 		SNY
$4.9B 		AMGN
$3.6B 		GSK
$3.0B 		AZN
$2.5B 		BMY
$2.2B 		PFE
-$0 		GILD
-$0 		MRK
-$0 		LLY
-$0
Long Term Debt $27.6 Billion 5/12 ABBV
$60.3B		 AMGN
$56.5B		 BMY
$49.0B		 JNJ
$30.7B		 AZN
$27.6B		 NVS
$22.9B		 GSK
$18.8B		 SNY
$14.8B		 PFE
$0		 GILD
$0		 MRK
$0		 LLY
$0
PE 32.20 5/12 GILD
279.92		 ABBV
82.97		 LLY
76.30		 AMGN
40.30		 AZN
32.20		 JNJ
27.59		 GSK
23.82		 SNY
19.10		 NVS
18.26		 PFE
18.08		 MRK
12.97		 BMY
-1.00
PS 4.19 7/12 LLY
17.94		 ABBV
6.31		 AMGN
4.94		 GILD
4.67		 JNJ
4.37		 NVS
4.30		 AZN
4.19		 MRK
3.46		 BMY
2.49		 PFE
2.28		 SNY
2.15		 GSK
1.52
PB 5.54 5/12 ABBV
105.66		 LLY
56.42		 AMGN
28.05		 BMY
7.33		 AZN
5.54		 JNJ
5.43		 MRK
4.98		 NVS
4.94		 GSK
4.69		 GILD
2.28		 SNY
1.64		 PFE
1.57
PC 41.28 2/12 ABBV
64.34		 AZN
41.28		 NVS
19.03		 SNY
17.18		 GSK
16.61		 JNJ
16.10		 AMGN
13.77		 BMY
11.61		 PFE
-1.00		 GILD
-1.00		 MRK
-1.00		 LLY
-1.00
Liabilities to Equity 1.55 5/12 ABBV
39.64		 AMGN
14.63		 BMY
4.67		 GSK
3.39		 AZN
1.55		 JNJ
1.52		 NVS
1.32		 SNY
0.71		 GILD
0.00		 PFE
-1.00		 MRK
-1.00		 LLY
-1.00
ROA 0.07 3/12 NVS
12% 		JNJ
8% 		AZN
7% 		GSK
6% 		SNY
6% 		AMGN
4% 		ABBV
3% 		GILD
1% 		BMY
-10% 		PFE
-100% 		MRK
-100% 		LLY
-100%
ROE 0.17 8/12 ABBV
129% 		LLY
74% 		AMGN
70% 		MRK
38% 		NVS
27% 		GSK
24% 		JNJ
20% 		AZN
17% 		PFE
9% 		SNY
9% 		BMY
-55% 		GILD
-100%
Current Ratio 1.65 4/12 SNY
2.42		 NVS
1.76		 JNJ
1.66		 AZN
1.65		 GSK
1.28		 BMY
1.22		 AMGN
1.07		 ABBV
1.03		 PFE
0.00		 MRK
0.00		 LLY
0.00		 GILD
-1.00
Quick Ratio 0.09 6/12 GILD
279.92		 ABBV
82.97		 LLY
76.30		 AMGN
40.30		 AZN
32.20		 JNJ
27.59		 GSK
23.82		 SNY
19.10		 NVS
18.26		 PFE
18.08		 MRK
12.97		 BMY
-1.00
Long Term Debt to Equity 0.68 5/12 ABBV}
18.15		 AMGN}
9.62		 BMY}
3.00		 GSK}
1.07		 AZN}
0.68		 NVS}
0.52		 JNJ}
0.43		 SNY}
0.17		 PFE}
0.00		 MRK}
0.00		 LLY}
0.00		 GILD}
-1.00
Debt to Equity 0.74 5/12 ABBV
20.19		 AMGN
10.23		 BMY
3.13		 GSK
1.24		 AZN
0.74		 NVS
0.71		 JNJ
0.51		 SNY
0.23		 PFE
0.00		 MRK
0.00		 LLY
0.00		 GILD
-1.00
Burn Rate 24.02 2/12 NVS
63.53		 AZN
24.02		 SNY
6.72		 GSK
5.75		 AMGN
4.75		 BMY
4.23		 ABBV
1.34		 PFE
0.00		 GILD
0.00		 MRK
0.00		 LLY
0.00		 JNJ
-33.99
Cash to Cap 0.02 7/12 BMY
0.09		 AMGN
0.07		 JNJ
0.06		 GSK
0.06		 SNY
0.06		 NVS
0.05		 AZN
0.02		 ABBV
0.02		 PFE
0.00		 GILD
0.00		 MRK
0.00		 LLY
0.00
CCR 1.30 6/12 BMY
56.40		 AMGN
7.02		 GSK
2.88		 GILD
1.67		 JNJ
1.41		 AZN
1.30		 NVS
1.09		 PFE
0.00		 MRK
0.00		 LLY
0.00		 ABBV
-307.14		 SNY
EV to EBITDA 56.67 9/12 ABBV}
779.54		 SNY}
292.80		 PFE}
198.77		 LLY}
131.41		 GSK}
101.98		 AMGN}
92.16		 JNJ}
67.66		 BMY}
63.10		 AZN}
56.67		 GILD}
54.82		 NVS}
45.84		 MRK}
32.04
EV to Revenue 4.65 6/12 LLY
17.94		 ABBV
7.40		 AMGN
6.38		 NVS
4.69		 GILD
4.67		 AZN
4.65		 JNJ
4.51		 MRK
3.46		 BMY
3.33		 GSK
2.84		 SNY
2.77		 PFE
2.28

Cookies

We use cookies to offer a better browsing experience. Cookies enhance site navigation, analyze site usage, and assist in our marketing efforts. By clicking Accept. you agree to the storing of cookies on your device. To refuse all non-required cookies, click on Decline.

Accept View Terms & Conditions